![]() |
|
|
Vol. 302, Issue 2, 725-730, August 2002
Research Department, Novartis Pharma AG, Basel, Switzerland
Dexamethasone increases the expression of adenosine
A3 receptors and augments degranulation in response to
their activation in the rat basophilic leukemia cell line, RBL-2H3. We
have studied the effects of dexamethasone on mast cell activation
induced by A3 receptor stimulation in vivo. Administration
of the A3 receptor agonist APNEA
[N6-2-(4 aminophenyl)ethyladenosine; 10-30
µg kg
1 i.v.] to anesthetized Sprague-Dawley
rats induced falls in blood pressure. Pretreatment with dexamethasone
(1 mg kg
1, i.p.,
24 h) blocked the hypotensive
response to APNEA but not those induced by the A1 receptor
agonist N6-cyclopentyladenosine, the
A2A receptor agonist
2-[p-(2-carboxyethyl)phenylamino]-5'-N-ethylcarboxamidoadenosine, or the mast cell degranulating agent compound 48/80 (100-300 µg kg
1, i.v.). APNEA (10 and 30 µg kg
1,
i.v.) and compound 48/80 (100 and 300 µg kg
1, i.v.)
increased plasma histamine concentrations dose dependently. Pretreatment with dexamethasone significantly inhibited the increases induced by the lower doses of each compound. APNEA induced
degranulation of mast cells in thymus but not in skin or skeletal
muscle, whereas compound 48/80 induced degranulation in each tissue.
Pretreatment with dexamethasone inhibited APNEA-induced degranulation
of mast cells in the thymus and slightly, yet significantly, reduced
degranulation induced by compound 48/80. Thus, in contrast to the
findings in RBL-2H3 cells in vitro, in the whole animal, dexamethasone
down-regulates the response of the mast cell to A3 receptor
activation. The qualitatively similar effects on compound 48/80 suggest
that dexamethasone suppresses mast cell responsiveness by modulating
site(s) downstream from the adenosine A3 receptor, possibly
at the level of the Gi family of trimeric GTP-binding proteins.